EVerZom raised a €1.1M funding round backed by institutional and private investors.

EVerZom, a Paris, France-based biopharmaceutical company specialized in the bioproduction of exosomes, announced the completion of €1.1 millio ($1.3M) funding round.

The money was raised from institutional and private investors including Bpifrance up to €500k via the French Tech Seed fund, the Ile-de-France region with €300k via the Innov'up Leader Pia device and €323k by a group of private business angels.

EVerZom, founded by president Jeanne Volatron, is working for the development of an exosome bioproduction platform. Exosomes are biological nanoparticles released by cells as an intercellular communication system to transport biomolecules. They have the ability to deliver therapeutics or regenerate tissue in several pathologies, including osteoarthritis, heart failure, and liver and kidney diseases, conditions which impact more than 150 million patients worldwide.